Drug intelligence / Profile preview

Zhile Capsule

Development stage: Preclinical
Lead developer: Zhejiang Shiqiang Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Zhile Capsule (知乐胶囊) is a Traditional Chinese Medicine (TCM) candidate developed by Zhejiang Shiqiang Pharmaceutical for the treatment of major depressive disorder (MDD). It is specifically formulated to address the TCM syndrome pattern of Qi and Yin deficiency with liver stagnation transforming into heat. The drug is currently undergoing clinical evaluation in China (e.g., trial CTR20244526) to assess its therapeutic efficacy and safety profile in patients with depression. As a botanical formulation, it likely exerts its effects through the synergistic action of multiple small molecule components derived from herbal extracts.

Brand names: Zhile Capsule
Other names: 知乐胶囊

Beyond the preview

Go deeper on Zhile Capsule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zhile Capsule.

Explore the full profile